Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system

Figure 1 PT1, PT2, and PT3 at baseline and 12 wk. PT1: Percentage of time below 3.9 mmol/L; PT2: Percentage of time between 3.9-7.8 mmol/L; PT3: Percentage of time above 7.8 mmol/L. P = 0.035, 0.005, and 0.005, respectively, after 12-wk treatment vs baseline.

Figure 2 Comparison of mean blood glucose and the area under curves of fasting and postprandial blood glucose at baseline and after treatment. A: Mean blood glucose from 0:00 to 24:00; B: Mean blood glucose from 6:00 to 8:00; C: Mean blood glucose from 8:00 to 10:00; D: Mean blood glucose from 13:00 to 15:00; E: Mean blood glucose from 18:00 to 20:00; F: Area under the curves of each time period. The data are denoted as mean ± SD. ^aP < 0.05, ^bP < 0.01, after 12-wk treatment vs baseline.